The Effects of Dupilumab on Allergic Contact Dermatitis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Allergic contact dermatitis
Focus Therapeutic Use

Most Recent Events

29 Oct 2023 The study protocol amended since the investigators will recruit 30 patients (previously 20 patients) with allergic contact dermatitis who have not improved with allergen avoidance up to 18 months (previously 6 months) after patch testing.
29 Oct 2023 Planned number of patients changed from 20 to 30.
29 Oct 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2023.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight